Amgen (AMGN) Accounts Payables (2009 - 2026)

Amgen has reported Accounts Payables for 18 years, with the latest figure at $2.9 billion in Q2 2026.

• On a quarterly basis, Accounts Payables fell 4.82% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 4.82% decrease from a year earlier, with the FY2025 full-year figure at $2.4 billion, up 24.06% from the prior year.
• Accounts Payables was $2.9 billion for Q2 2026 at Amgen, down from $2.9 billion in the prior quarter.
• The five-year high for Accounts Payables was $3.0 billion in Q2 2025, with the low at $1.2 billion in Q3 2022.
• Average Accounts Payables over 5 years is $2.0 billion, with a median of $1.8 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables retreated 5.92% in 2023, then surged 87.05% in 2024.
• Over 5 years, Accounts Payables stood at $1.6 billion in 2022, then rose by 1.15% to $1.6 billion in 2023, then advanced by 20.0% to $1.9 billion in 2024, then grew by 24.06% to $2.4 billion in 2025, then gained by 21.04% to $2.9 billion in 2026.
• The last three Accounts Payables figures came in at $2.9 billion (Q2 2026), $2.9 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.